PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Impact of mulberry leaf extract on type 2 diabetes (Mul-DM): A randomized, placebo-controlled pilot study.

Abstract Mulberry leaves have been used anecdotally in Asia to treat many disease states, including glucose abnormalities. Animal and human studies illustrate potential benefit of mulberry leaf extract (MLE) in type 2 diabetes mellitus (DM2). The purpose of this study is to evaluate the glycemic and safety effects of MLE in patients with DM2.
PMID
Related Publications

The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial.

Authors

Mayor MeshTerms

Morus

Keywords

Complementary and alternative medicine

Diabetes

Hemoglobin A1c

Herbal medicine

Mulberry leaf extract

Self-monitoring blood glucose

Journal Title complementary therapies in medicine
Publication Year Start




PMID- 28619294
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170627
LR  - 20170627
IS  - 1873-6963 (Electronic)
IS  - 0965-2299 (Linking)
VI  - 32
DP  - 2017 Jun
TI  - Impact of mulberry leaf extract on type 2 diabetes (Mul-DM): A randomized,
      placebo-controlled pilot study.
PG  - 105-108
LID - S0965-2299(17)30078-X [pii]
LID - 10.1016/j.ctim.2017.04.006 [doi]
AB  - AIMS: Mulberry leaves have been used anecdotally in Asia to treat many disease
      states, including glucose abnormalities. Animal and human studies illustrate
      potential benefit of mulberry leaf extract (MLE) in type 2 diabetes mellitus
      (DM2). The purpose of this study is to evaluate the glycemic and safety effects
      of MLE in patients with DM2. MATERIALS & METHODS: This randomized, double-blind, 
      placebo-controlled pilot study evaluated MLE (1000mg standardized) versus
      matching placebo given three times daily with meals. Patients (n=24) were
      included if they had DM2 on single or combination oral therapy with a stable
      hemoglobin A1C (A1C). A 2-week placebo run-in (baseline) was followed by
      initiation of randomized medication for 3 months. Primary endpoints were change
      in A1C and self-monitoring blood glucoses (SMBG). Safety was also evaluated.
      RESULTS: Of 24 patients enrolled, 17 patients completed the study. Post-prandial 
      SMBG was significantly decreased at 3 months in the MLE group versus baseline
      (16.1%; p<0.05). This improvement in post-prandial SMBG persisted when compared
      to placebo (18.2%; p<0.05). A1C decreased from 7.30% at baseline to 6.94% in the 
      MLE group but did not reach statistical significance (p=0.079). There was no
      difference in A1C between MLE and placebo. A significant 15% increase occurred in
      serum creatinine when the MLE group was compared to baseline or placebo (p<0.05
      for both). There was no significant effect on weight, fasting SMBG, blood
      pressure, hypoglycemia, or other safety evaluation markers. CONCLUSIONS: These
      results suggest that mulberry leaf extract may be a useful complementary mealtime
      glucose option for patients with DM2. ClinicalTrials.gov Identifier NCT00795704.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Riche, Daniel M
AU  - Riche DM
AD  - The University of Mississippi School of Pharmacy, Jackson, MS, United States; The
      University of Mississippi Medical Center, Jackson, MS, United States. Electronic 
      address: [email protected]
FAU - Riche, Krista D
AU  - Riche KD
AD  - St. Dominic Hospital, Jackson, MS, United States.
FAU - East, Honey E
AU  - East HE
AD  - Premier Medical Group, Jackson, MS, United States.
FAU - Barrett, Elizabeth K
AU  - Barrett EK
AD  - The University of Mississippi School of Pharmacy, Jackson, MS, United States.
FAU - May, Warren L
AU  - May WL
AD  - The University of Mississippi Medical Center, Jackson, MS, United States.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170427
PL  - Scotland
TA  - Complement Ther Med
JT  - Complementary therapies in medicine
JID - 9308777
RN  - 0 (Blood Glucose)
RN  - 0 (Hemoglobin A, Glycosylated)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Plant Extracts)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Blood Glucose Self-Monitoring
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Hemoglobin A, Glycosylated
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Morus
MH  - Plant Extracts/*therapeutic use
MH  - Prospective Studies
OTO - NOTNLM
OT  - Complementary and alternative medicine
OT  - Diabetes
OT  - Hemoglobin A1c
OT  - Herbal medicine
OT  - Mulberry leaf extract
OT  - Self-monitoring blood glucose
EDAT- 2017/06/18 06:00
MHDA- 2017/06/28 06:00
CRDT- 2017/06/17 06:00
PHST- 2017/02/02 [received]
PHST- 2017/03/31 [revised]
PHST- 2017/04/24 [accepted]
AID - S0965-2299(17)30078-X [pii]
AID - 10.1016/j.ctim.2017.04.006 [doi]
PST - ppublish
SO  - Complement Ther Med. 2017 Jun;32:105-108. doi: 10.1016/j.ctim.2017.04.006. Epub
      2017 Apr 27.